Celltech/Bayer Bay10-3356 to enter Phase III U.S. trials for septic shock in 1997.
CELLTECH/BAYER BAY10-3356 TO ENTER PHASE III FOR SEPTIC SHOCK IN 1997 in the U.S. if pivotal trials of the companies' predecessor compound for septic shock, Bay-X1351, shows proof of principle, Celltech Group Chief Executive Peter Fellner, PhD, told a UBS Securities' life sciences conference in London April 16. Development of Bay10-3356 for septic shock will run about two years behind development of the murine Bay-X1351 for the indication, Fellner said. Bayer is conducting pivotal trials of Bay-X1351 ("The Pink Sheet" April 14, T&G-4).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth